argenx SE

Brussels Stock Exchange ARGX.BR

argenx SE Gross Profit Margin for the year ending December 31, 2023: 90.39%

argenx SE Gross Profit Margin is 90.39% for the year ending December 31, 2023, a -2.63% change year over year. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.
  • argenx SE Gross Profit Margin for the year ending December 31, 2022 was 92.83%, a 3,715.68% change year over year.
  • argenx SE Gross Profit Margin for the year ending December 31, 2021 was -2.57%, a 99.56% change year over year.
  • argenx SE Gross Profit Margin for the year ending December 31, 2020 was -577.68%, a -280.59% change year over year.
  • argenx SE Gross Profit Margin for the year ending December 31, 2019 was -151.78%, a -251.78% change year over year.
Key data
Date Gross Profit Margin Operating Income Margin EBT Margin Net Income Margin
Market news
Loading...
Brussels Stock Exchange: ARGX.BR

argenx SE

CEO Mr. Timothy Van Hauwermeiren EMBA, M.Sc.
IPO Date July 10, 2014
Location Netherlands
Headquarters Willemstraat 5
Employees 1,148
Sector Health Care
Industries
Description

argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy in Phase III clinical trials; bullous pemphigoid and idiopathic inflammatory myopathy in Phase II/III clinical trials; and ENHANZE SC in Pre-clinical study. The company is also developing immunology innovation programs, including cusatuzumab for hematological cancer, as well as high risk MDS; ARGX-119, an antibody that targets muscle-specific tyrosine kinase stage; ARGX-117 for severe autoimmune indications; ARGX-118 for airway inflammation; and ARGX-120 to treat autoimmune diseases. In addition, its partnered product candidates include ARGX-115 for the treatment of cancer; ARGX-112 to treat interleukin-22 receptor; and ARGX-114, an antibody directed against the MET receptor. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., University of Texas, BioWa, Inc., Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.

Similar companies

GLPG.AS

Galapagos NV

USD 24.20

-0.41%

MELE.BR

Melexis NV

USD 60.03

0.18%

UCB.BR

UCB SA

USD 195.15

-0.39%

StockViz Staff

January 15, 2025

Any question? Send us an email